Cosmo Pharmaceuticals NV (OTCPK:CMOPF)

$ 95 0 (0%) Market Cap: 1.40 Bil Enterprise Value: 1.25 Bil PE Ratio: 18.02 PB Ratio: 2.50 GF Score: 76/100

Half Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript
Jul 24, 2024

$80.25

Earnings
Cosmo Pharmaceuticals NV Investor Day Transcript
Mar 20, 2024
Full Year 2023 Cosmo Pharmaceuticals NV Earnings Call Transcript
Mar 20, 2024

$75.9 (+1.07%)

Earnings
Half Year 2023 Cosmo Pharmaceuticals NV Earnings Call Transcript
Jul 26, 2023

$50.3

Earnings
Full Year 2022 Cosmo Pharmaceuticals NV Earnings Call Transcript
Mar 23, 2023

$61 (+0.58%)

Earnings
Half Year 2022 Cosmo Pharmaceuticals NV Earnings Call Transcript
Jul 28, 2022

$47.5

Earnings
Full Year 2021 Cosmo Pharmaceuticals NV Earnings Call Transcript
Mar 23, 2022

$58.99

Earnings
Half Year 2021 Cosmo Pharmaceuticals NV Earnings Call Transcript
Jul 30, 2021

$96

Earnings
Cosmo Pharmaceuticals NV to Discuss GI Genius™ Call (Q&A Session) Transcript
May 04, 2021
Full Year 2020 Cosmo Pharmaceuticals NV Earnings Call Transcript
Mar 26, 2021

$89.2

Earnings
Half Year 2020 Cosmo Pharmaceuticals NV Earnings Call Transcript
Jul 30, 2020

$76.75

Earnings
Full Year 2019 Cosmo Pharmaceuticals NV Earnings Call Transcript
Apr 03, 2020

$76.75

Earnings
Half Year 2019 Cosmo Pharmaceuticals NV Earnings Call Transcript
Jul 30, 2019

$84.85

Earnings
Cosmo Pharmaceuticals NV R&D Day Transcript
May 08, 2019
Full Year 2018 Cosmo Pharmaceuticals NV Earnings Call Transcript
Mar 29, 2019

$84.85

Earnings

Half Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript

Jul 24, 2024 / 12:00PM GMT

Release Date Price: $80.25

Transcript

Hazel Winchester

Cosmo Pharmaceuticals NV - Head of Investor Relations

Hello, everyone, and welcome to Cosmos half year results 2024 webcast presentation. I'm Hazel Winchester, Head of Investor Relations at Cosmo, and it's a privilege to open today's session.

In a few moments, you will hear from Giovanni Di Napoli, our CEO, who we call Gio; and Niall Donnelly, our CFO, both will provide a comprehensive overview of our financial performance for the first half of the year, discuss key operational highlights and outline the strategic initiatives that have driven our progress. Additionally, they will share our outlook for the remainder of the year.

Thank you for joining us today. I will now hand over to Gio, who will kick off our presentation.

Giovanni Di Napoli

Cosmo Pharmaceuticals NV - Chief Executive Officer

Thank you, Hazel. Good afternoon, everyone. Thank you for joining us today for Cosmo Pharmaceuticals 2024 half year earnings call. My name is Giovanni Di Napoli, and I am honored to speak with you as the new CEO of this remarkable

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.